PI3K inhibitors (MD Anderson Cancer Center)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePI3K inhibitors (MD Anderson Cancer Center)
Drug Alias NamePhosphoinositide 3-kinase inhibitors (MD Anderson Cancer Center)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitors
TargetsPI3-kinase class I
Therapy Area/IndicationsBrain Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsBrain Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A